Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University of Pennsylvania and The University of Colorado Anschutz Medical Campus. An oncogene is a mutated version of a … Continued
Recent OCRA-funded research has resulted in the creation of a new bioinformatics tool that holds potential for predicting the best treatment combinations for cancer patients. Bioinformatics is a scientific discipline that enables researchers to collect, process and analyze a vast amount of biological and medical data via computers and statistical techniques. In the case of … Continued
Dr. Sandra Cascio of Magee-Womens Research Institute is a 2021 recipient of OCRA’s Early Career Investigative Grant. With her project, “EGFL6 as a New Regulator of Myeloid Cell Expansion and Function in HGSOC,” Dr. Cascio seeks to better understand ovarian tumors’ microenvironments and, ultimately, to overcome ovarian cancer resistance to immunotherapy, opening up a new … Continued
Dr. Martin Cannon, of University of Arkansas for Medical Sciences (UAMS), is a 2021 recipient of OCRA’s Collaborative Research Development Grant. With his project, “Understanding and Targeting Myeloid Populations in Ovarian Cancer,” Dr. Cannon seeks to better understand the behavior of a type of immune cell that currently helps ovarian cancer tumors grow, in order … Continued
The following is a press release from Ovarian Cancer Research Alliance and Cancer Research Institute: NEW YORK, May 11, 2022 — The Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA) announced today that the first patients have been dosed in their new multi-center platform clinical trial testing novel cancer immunotherapy combinations in patients … Continued
Many exciting updates about progress against ovarian cancer were presented at this year’s Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer — the largest meeting of gynecologic cancer experts in the world. This April, gynecologic oncologist and ovarian cancer expert Dr. Sarah Adams joined OCRA for an interactive webinar reporting on the highlights (in … Continued
A therapeutic strategy that targets key tumor proteins shows promise for treating the most common subtype of ovarian cancer, according to a recent study led by OCRA grantee Duygu Ozmadenci, PhD, of the University of California, San Diego Moores Cancer Center. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, with approximately 75% of epithelial ovarian cancers … Continued
Dr. Benoît Brangantini, of Mayo Clinic, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With his project, “Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM,” Dr. Bragantini aims to better understand how DNA damage and repair mechanisms can lead to ovarian cancer, and how these processes can be controlled to prevent ovarian … Continued
Some ovarian cancers are genetically linked to the gynecologic disorder known as endometriosis, according to recent findings from an international team of researchers. Endometriosis is a disease in which tissue that normally lines the inside of the uterus — the endometrium — grows outside the uterus. Though endometriosis is classified as a benign disorder, it … Continued
Key recommendations for improving care of ovarian cancer patients in the United States have been published as part of a collaborative, in-depth initiative spearheaded by the Association of Community Cancer Centers (ACCC) and involving a joint partnership between OCRA, the Society of Gynecologic Oncology, the National Society of Genetic Counselors, and the Association for Molecular Pathology. The initiative was guided … Continued
In promising news on the prevention front, one surgical procedure that leaves the ovaries intact may greatly reduce the risk of ovarian cancer. Recent research findings show that the surgical removal of fallopian tubes in a procedure known as an opportunistic salpingectomy may prevent the most common subtype of ovarian cancer from developing. The procedure … Continued
This may be a short month, but it’s not short on all the many ways to get involved. In the meantime, we hope you feel the Valentine love from all of us at OCRA. Advocacy Patient Support & Programs Events Research Ways to Give
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
